1.39
+0.165(+13.47%)
Currency In USD
| Previous Close | 1.23 |
| Open | 1.22 |
| Day High | 1.46 |
| Day Low | 1.21 |
| 52-Week High | 3.45 |
| 52-Week Low | 1.01 |
| Volume | 1.71M |
| Average Volume | 1.66M |
| Market Cap | 393.74M |
| PE | -2.01 |
| EPS | -0.69 |
| Moving Average 50 Days | 1.36 |
| Moving Average 200 Days | 2.27 |
| Change | 0.17 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $79.75 as of May 09, 2025 at a share price of $1.39. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $224.92 as of May 09, 2025 at a share price of $1.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca to Present at the Bank of America Securities Health Care Conference
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, tod
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
GlobeNewswire Inc.
Apr 29, 2025 8:05 PM GMT
ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway sign
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
GlobeNewswire Inc.
Mar 25, 2025 8:31 PM GMT
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the